中国医疗卫生事业发展报告.2017：中国药物政策与管理专题

内容简介

本书围绕新时期医药卫生体制改革和健康中国战略需要解决的关键问题，全面分析了我国药物政策与管理制度的改革理念与路径、制度设计与发展特色，以理论分析和实证研究为支撑，结合我国药品审批和质量监管、生产、流通、使用等关键体制和机制改革问题，重点分析基本药物制度、药品供应保障体系与医保支付方式改革、破除以药养医背景下的公立医院改革、三医联动改革的药物政策、药品透明监管机制、基本医疗保险药品目录管理、国家执业药师制度，以及罕见病、抗菌药物、中药等药物使用现状及问题，对今后健康中国战略实施提出了前瞻性、可操作性的政策咨询和建议，为我国完善药品供应保障制度、基本药物制度，提出重要政策转化依据。

Focusing on the key issues that need to be solved in the reform of the medical and health system and the strategy of healthy China in the new era, this book comprehensively analyzes the reform concept and path, system design and development characteristics of China's drug policy and management system, with the support of theoretical analysis and empirical research, combined with the key system and mechanism reform issues such as drug approval and quality supervision, production, circulation and use in China, focuses on analyzing the reform of the basic drug system, the drug supply guarantee system and the medical insurance payment method, and breaking the reform of public hospitals under the background of using medicine to support medicine. The drug policy, drug transparency supervision mechanism, basic medical insurance drug list management, national licensed pharmacist system, and the current situation and problems of the use of rare diseases, antibacterial drugs, traditional Chinese medicines and other drugs have put forward forward-looking and operable policy consultation and suggestions for the future implementation of the Healthy China strategy, and put forward important policy transformation basis for China to improve the drug supply guarantee system and basic drug system.（AI翻译）

作者简介

方鹏骞:（编著）

方鹏骞，华中科技大学同济医学院教授，健康政策与管理研究院院长，博士生导师，南京医科大学特聘教授，教育部哲学社会科学研究重大课题攻关项目首席专家，国家社会科学基金重大项目首席专家，国家自然科学基金重点项目负责人。